Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

Switzerland

University Hospital Zurich, Division of Nephrology, Zurich, Canton of Zurich

Cantonal Hospital Graubuenden, Chur, Kanton Graubünden